The nation of Zimbabwe has declined a substantial US healthcare agreement valued at 367 million US dollars (£272m) spanning five years over the United States' insistence on sensitive biological samples.
This move became public after a official document from December was disclosed, indicating that Head of State Emmerson Mnangagwa felt the arrangement was "lopsided".
A government representative later explained that the United States was requesting biological samples for scientific study and commercial purposes while was not willing to share the resulting advantages from future treatments.
"We must now begin the challenging and unfortunate task of winding down our health assistance in Zimbabwe," stated American envoy to Zimbabwe Pamela Tremont publicly.
Her embassy noted the United States had furnished over $1.9bn for health programmes to Zimbabwe over the last twenty years.
A physicians' group in Zimbabwe has called for more dialogue to secure a deal agreeable to all parties so the nation's vital HIV treatment initiative can continue.
Broader Background
This rejection comes after a similar case in neighbouring Kenya, where a court blocked a similar deal with the US following concerns were filed about the safety of citizens' medical information.
After returning to office recently, US President Donald Trump has drastically cut foreign aid and closed the US Agency for International Development (USAID).
USAID had overseen aid for the American government, but Trump claimed its expenditure was "wasteful" and his government was pursuing direct bilateral deals to boost openness and responsibility.
According to statements, Sixteen African countries have to date agreed to similar agreements, constituting more than $18.3bn in committed funds.
Details of the Declined Deal
This assistance for Zimbabwe would have supported "combating HIV/Aids, tuberculosis, malaria, healthcare for mothers and children, and disease outbreak preparedness.
"We are confident this partnership could have provided significant benefits for the people of Zimbabwe, especially the 1.2 million men, women and children currently on HIV treatment through American-funded programmes," the Ambassador commented.
However, government spokesperson Nick Mangwana said the arrangement was "unequal".
"The proposal required Zimbabwe to share its biological resources and data for a long time, with no equivalent promise of benefiting from any medical innovations – like vaccines, diagnostics, or treatments – that might result from that provided information," he stated.
"Effectively, our country would provide the basic resources for medical research without any certainty that the resulting innovations would be accessible to our citizens if a new disease outbreak emerge."
Sovereignty and Global Health
He also noted that the US's withdrawal from the World Health Organization (WHO) and its push of one-on-one health agreements were undermining structures previously set up via the global health agency.
The spokesperson cited its Pathogen Access and Benefit Sharing scheme created to deal with future pandemics.
"This mechanism is intended to ensure that when a country contributes its samples, the benefits – such as vaccines and treatments – are shared equitably, not commercialised solely by those with the funds to create them."
These objections regarding the US deal "should not be misconstrued as opposition to America," Mangwana stressed.
"We encourage further discussions with our American counterparts on how subsequent co-operation might be structured in a way that respects the sovereignty and interests of each country."
Medical Community Response
The Zimbabwe College of Public Health Physicians (ZCPHP) said it understood the official position, but urged that negotiations need to persist considering a large portion of the country's Aids initiatives depended on foreign aid.
"In cases where specific concerns arise, such as those relating to data governance or implementation frameworks, these can frequently be resolved through detailed discussion and mutually agreed protections," it commented.
This impasse highlights the complex tensions between accepting vital international aid and protecting local interests in an increasingly data-driven world.